Latest news
RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy - BioPharma APACBioPharma APAC · Sun, 09 Aug 2026 18:30:13 GMTRiboX’s Circular RNA CAR-T IND Clearance Forces the Industry to Rethink Everything It Knows About Cell Therapy Trial Design - The Clinical Trial VanguardThe Clinical Trial Vanguard · Sun, 09 Aug 2026 07:28:07 GMTJ&J secures option to acquire Sail in USD 3.5 billion in vivo CAR-T alliance - AllSciAllSci · Fri, 31 Jul 2026 13:01:13 GMTCREATE Medicines Expands Targeted In Vivo CAR Platform Through Strategic Research Collaboration and Exclusive License Agreement with Monash University - PR NewswirePR Newswire · Fri, 31 Jul 2026 07:00:00 GMTJ&J takes $2.58bn option to buy in vivo CAR-T firm Sail - pharmaphorum.compharmaphorum.com · Thu, 30 Jul 2026 10:54:17 GMTJ&J pays Sail $785M, charting course to possible in vivo CAR-T buyout - Fierce BiotechFierce Biotech · Thu, 30 Jul 2026 07:00:00 GMTJ&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B - BioPharma DiveBioPharma Dive · Thu, 30 Jul 2026 07:00:00 GMTCREATE Medicines Receives Approval to Initiate First-in-Human Phase 1/2 Clinical Trial of In Vivo CAR-T Candidate CRT-402 for Autoimmune Diseases - PR NewswirePR Newswire · Thu, 30 Jul 2026 07:00:00 GMT